Adaptation of Alveolar-capillary Diffusion at Effort of Subjects Suffering From Complex Congenital Heart Disease

Complex Congenital Heart Disease Clinical Trial

— CAR-DIFF  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02561975
• Other study ID #: 9375
• Status: Completed
• Phase: N/A
• First received: January 12, 2015
• Last updated: February 6, 2018
• Start date: December 2014
• Est. completion date: December 2017

Study information

• Verified date: February 2018
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An injury of haematosis in post ischemic chronic heart failure limits the clinic tolerance.

There is a correlation between injury of pulmonary diffusing, chronic heart failure intensity and aerobic physic ability evaluated by an heart-rate maximal exercise tolerance test (VO2 max). This injury is a new follow-up parameter of cardiac function for the adult.

The nature of damage (vascular or membrane) can be determined by the measure of double pulmonary diffusing capacity to carbon monoxide (CO) associated to nitric oxide (NO).

Today, in chronic heart failure consecutive to a congenital heart disease, there is no data on evolution of membrane and capillar factors.It is impossible to predict if membrane damage will be the best factor correlated to the VO2max in patients suffering from complex congenital heart disease.

Assessing these parameters could be an comparative evaluation of heart-rate exercise tolerance test with VO2max and an early control of his damage without risks related to heart-rate maximal exercise and independently of age, sex, hemoglobin, type of heart disease.These results would have an early prognostic value that would permit to refine the follow-up and the treatment.

The main objective of this trial is to assess the statistic correlation between the membrane injury of alveolar-capillary diffusing at rest and aerobic physic ability restriction in children and adults suffering from complex congenital heart disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: December 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years and older

Eligibility

Inclusion Criteria:

• Informed consent

• Age > 8 years- female and male patients

• Heart-rate exercise tolerance test planned in the usual patient's follow-up

• Congenital heart disease: single ventricle with Fontan circulation or bicavo-bipulmonary bypass or systemic right ventricle or pulmonary failure

Exclusion Criteria:

• Chronic or acute intercurrent respiratory disease

• In exclusion period in relation with another trial or for

• Participation to another study

• Patient doesn't benefit from an insurance disease regimen

• Pregnant woman or breast-feeding, law-protected person, vulnerable person

Related Conditions & MeSH terms

• Complex Congenital Heart Disease
• Heart Defects, Congenital
• Heart Diseases
• Pulmonary Failure
• Single Ventricle With Fontan Circulation or Bicavo-bipulmonary Bypass
• Systemic Right Ventricle

Intervention

Other:
• Double pulmonary diffusing
Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity. With the expired air, some parameters will be assessed: Alveolar volume (VA) Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin) Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc

Locations

Country	Name	City	State
France	CHU Montpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Membrane ductance (Dm) correlated with VO2max	membrane ductance (Dm) is assessed by double pulmonary diffusing at rest	at the time of evaluation at rest (15 minutes before exercise)
Secondary	capillary pulmonary recruitment during exercise correlated with VO2max. (capillary pulmonary volume 3 minutes after the end of a maximal exercise minus capillary pulmonary volume at rest)	capillary pulmonary volume 3 minutes after the end of a maximal exercise minus capillary pulmonary volume at rest	at the time of evaluation at rest (15 minutes before exercise) and 3 minutes after the end of a maximal exercise
Secondary	parameters assessed during measure TLCO/TLNO of double pulmonary diffusing at rest correlated with electrocardiographic parameters	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO and Dm/Vc	at the time of evaluation at rest (15 minutes before exercise)
Secondary	parameters assessed during measure TLCO/TLNO of double pulmonary diffusing 3 minutes after the end of a maximal exercise correlated with electrocardiographic parameters	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc	3 minutes after the end of a maximal exercise
Secondary	parameters assessed during measure TLCO/TLNO of double pulmonary diffusing 10 minutes after the end of a maximal exercise correlated with electrocardiographic parameters	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc	10 minutes after the end of a maximal exercise
Secondary	parameters assessed during measure TLCO/TLNO of double pulmonary diffusing at rest correlated with VO2max	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO and Dm/Vc	at the time of evaluation at rest (15 minutes before exercise)
Secondary	parameters assessed during measure TLCO/TLNO of double pulmonary diffusing at rest correlated with clinic dyspnea (NYHA)	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO and Dm/Vc	at the time of evaluation at rest (15 minutes before exercise)
Secondary	parameters assessed during measure TLCO/TLNO of double pulmonary diffusing 3 minutes after the end of a maximal exercise correlated with VO2max	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc	3 minutes after the end of a maximal exercise
Secondary	diffusing 3 minutes after the end of a maximal exercise correlated with clinic dyspnea (NYHA)	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc	3 minutes after the end of a maximal exercise
Secondary	parameters assessed during measure TLCO/TLNO of double pulmonary diffusing 10 minutes after the end of a maximal exercise correlated with VO2max	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc	10 minutes after the end of a maximal exercise
Secondary	diffusing 10 minutes after the end of a maximal exercise correlated with clinic dyspnea (NYHA)	parameters assessed during measure TLCO/TLNO of double diffusing are TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc	10 minutes after the end of a maximal exercise